Ceftibuten

Drug Profile

Ceftibuten

Alternative Names: 7432-S; Cedax; Cepifran; Isocef; SCH 39720; Seftem

Latest Information Update: 06 Apr 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shionogi
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacterial infections; Otorhinolaryngological infections; Respiratory tract infections

Most Recent Events

  • 25 Mar 2010 Pernix Therapeutics Holdings acquires ceftibuten from Shionogi
  • 31 Aug 2004 Biovail has terminated its sub-licensing and manufacturing agreements for ceftibuten in USA
  • 31 Aug 2004 Ceftibuten has been licensed to Shionogi in USA and Puerto Rico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top